SkinBioTherapeutics (LON:SBTX) Trading Up 7.9% – What’s Next?

Shares of SkinBioTherapeutics plc (LON:SBTX) shot up 7.9% during trading on Friday . The company traded as high as GBX 12.50 and last traded at GBX 12.13. Approximately 852,400 shares were traded during trading, a decline of 78% from the average session volume of 3,837,103 shares. The stock had previously closed at GBX 11.25.

SkinBioTherapeutics Price Performance

The company has a current ratio of 6.14, a quick ratio of 10.01 and a debt-to-equity ratio of 11.77. The company has a market capitalization of £31.45 million, a PE ratio of -39.15 and a beta of 0.12. The stock’s 50-day moving average is GBX 9.78 and its two-hundred day moving average is GBX 12.16.

SkinBioTherapeutics (LON:SBTX) last released its earnings results on Monday, June 8th. The company reported GBX (0.31) EPS for the quarter. SkinBioTherapeutics had a negative net margin of 8.73% and a negative return on equity of 5.25%. The business had revenue of GBX 217 million for the quarter.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.